Dougherty et al., Philadelphia, United States. In J Assist Reprod Genet, Jan 2016
PURPOSE: To determine if exposure to progesterone alone is sufficient to increase the production of the immunomodulatory protein known as the progesterone induced blocking factor (PIBF).
Yang et al., Guangzhou, China. In Nan Fang Yi Ke Da Xue Xue Bao, Jun 2015
OBJECTIVE: To explore progesterone-induced blocking factor (PIBF) expression in the placenta and blood of patients with severe preeclampsia and its relationship with immune tolerance imbalance.
Fatušić et al., Tuzla, Bosnia and Herzegovina. In J Reprod Immunol, Jun 2015
The objective of this study was to analyze the maternal serum concentration of progesterone-induced blocking factor (PIBF) with regard to the prediction and the interval between sampling and the onset of preterm birth.
MATERIALS AND METHODS: A newly developed enzyme linked immunoabsorbent assay (ELISA) assay was used to measure PIBF in the sera of six women with various gynecologic cancers and compare them to five controls (three with benign tumors and two having gynecologic procedures for non-tumors.
Tan et al., Singapore, Singapore. In Gynecol Endocrinol, 2014
This study seeks to establish progesterone and progesterone-induced blocking factor (PIBF) levels as predictors of subsequent completed miscarriage among women presenting with threatened miscarriage between 6 and 10 weeks of gestation.
Camacho-Arroyo et al., Mexico. In J Steroid Biochem Mol Biol, 2014
Recently, it has been found that P4 induces the growth of several tumors through the up-regulation of progesterone-induced blocking factor (PIBF), a protein that has been related to the immunologic and proliferative actions of P4.
Kyurkchiev et al., Sofia, Bulgaria. In Cell Mol Neurobiol, 2014
Progesterone-induced blocking factor (PIBF) is an immunomodulatory protein with known role in the regulation of the immune response in the reproductive system.
Sarumi et al., York, United States. In Anticancer Res, 2014
The aim of the present study was to determine if rapidly advancing chronic lymphocytic leukemia responds to mifepristone therapy, and if so, is this effect related to increased expression of the progesterone-induced blocking factor?
Sarumi et al., York, United States. In Anticancer Res, 2014
The theory of its mechanism is that it prevents the secretion of a progesterone-induced immunomodulatory protein in the tumor microenvironment, or in the tumor cell itself, called the progesterone-induced blocking factor, which inhibits natural killer cells from attacking the cancer cell.
Mandžić et al., Tuzla, Bosnia and Herzegovina. In J Reprod Immunol, 2011
increased serum levels after dydrogesterone supplementation in women with threatened preterm delivery; positive correlation with the length of gestation
Palkovics et al., Pécs, Hungary. In J Reprod Immunol, 2009
A protein called progesterone-induced blocking factor (PIBF), by inducing a Th2-dominant cytokine production mediates the immunological effects of progesterone.
Szekeres-Bartho, Pécs, Hungary. In Immunotherapy, 2009
Several immunological effects of progesterone are mediated by progesterone-induced blocking factor--the product of a progesterone-induced gene in lymphocytes.